- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04917757
Clinical Outcome of Autonomous Cortisol Secretion in Adrenal Incidentalomas (NAPACA)
June 7, 2021 updated by: Martin Fassnacht, Wuerzburg University Hospital
Clinical Outcome of Autonomous Cortisol Secretion in Adrenal Incidentalomas - Substudy of the ENSAT (European Network for the Study of Adrenal Tumor) Registry
The primary aim of the study is to assess mortality and cardiovascular events potentially linked to cortisol excess in patients with adrenal incidentalomas stratified by cortisol values following the 1-mg overnight dexamethasone test.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
The NAPACA Outcome Study is part of the ENSAT Registry (https://registry.ensat.org/)
Study Type
Observational
Enrollment (Actual)
4374
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
patients with adrenal incidentaloma
Description
Inclusion Criteria:
- age ≥18 years
- adrenal incidentaloma (≥ 1cm) detected by cross-sectional imaging between January 1, 1996 and December 31, 2015
- imaging characteristics suggestive for an adrenal adenoma or excluded malignancy by follow-up imaging
- availability of a 1 mg dexamethasone test result
- follow-up data on living status and occurrence of cardiovascular events
- follow-up duration of at least 36 months.
Exclusion Criteria:
- proven pheochromocytoma, primary hyperaldosteronism or adrenocorticotropic hormone (ACTH)-dependent Cushing's syndrome
- clinical features suggestive for overt Cushing's syndrome; urinary free cortisol (UFC) ≥ 2-fold higher than the upper limit of normal of the local assay
- any active malignancy (including adrenocortical cancer) at the time of primary diagnosis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Other
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mortality
Time Frame: From date of primary diagnosis of the adrenal incidentaloma until December 31, 2018
|
death
|
From date of primary diagnosis of the adrenal incidentaloma until December 31, 2018
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cardiovascular morbidity
Time Frame: From date of primary diagnosis of the adrenal incidentaloma until December 31, 2018
|
Cardiovascular (CV) events (myocardial infarction, percutaneous coronary intervention, coronary bypass, stroke, deep vein thrombosis, and pulmonary embolism)
|
From date of primary diagnosis of the adrenal incidentaloma until December 31, 2018
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: Martin Fassnacht, MD, Wuerzburg University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2015
Primary Completion (Actual)
May 31, 2021
Study Completion (Anticipated)
December 31, 2021
Study Registration Dates
First Submitted
June 1, 2021
First Submitted That Met QC Criteria
June 1, 2021
First Posted (Actual)
June 8, 2021
Study Record Updates
Last Update Posted (Actual)
June 10, 2021
Last Update Submitted That Met QC Criteria
June 7, 2021
Last Verified
June 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Endocrine Gland Neoplasms
- Adrenal Gland Diseases
- Adrenal Cortex Neoplasms
- Adrenal Cortex Diseases
- Adrenal Gland Neoplasms
- Adrenocortical Adenoma
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Dexamethasone
Other Study ID Numbers
- NAPACA-Outcome
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
IPD Plan Description
not yet decided.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adrenal Incidentaloma
-
University Medical Centre LjubljanaUniversity Rehabilitation Institute, Republic of Slovenia; University of Ljubljana...Unknown
-
Istanbul UniversityCompletedAdrenal Cortex NeoplasmsTurkey
-
Chongqing Medical UniversityCompletedPrevalence | Adrenal IncidentalomaChina
-
Region SkaneCompletedCortisol Overproduction | Adrenal IncidentalomaSweden
-
The Cleveland ClinicRecordati Rare DiseasesNot yet recruitingMild Autonomous Cortisol Secretion (MACS)United States
-
Mansoura UniversityCompleted
-
University of Roma La SapienzaRecruitingAdrenal Tumor | Adrenal Incidentaloma | HypercortisolismItaly
-
University Medical Center GroningenRadboud University Medical Center; Maastricht University Medical Center; UMC... and other collaboratorsRecruitingAdrenocortical Carcinoma | Adrenal IncidentalomaNetherlands
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...RecruitingAdrenal Incidentaloma | Autonomous Cortisol Secretion | Non-functioning Adrenal AdenomasChina
-
University Hospital, BordeauxCompletedAdrenal IncidentalomasFrance, Germany, Italy
Clinical Trials on 1mg Dexamethasone test
-
University of EdinburghNHS LothianCompleted
-
Chong Kun Dang PharmaceuticalCompleted
-
Boryung Pharmaceutical Co., LtdCompletedSmoking CessationKorea, Republic of
-
Woman'sNovo Nordisk A/SRecruitingPre Diabetes | Postpartum DisorderUnited States
-
Abalonex, LLCNot yet recruitingTraumatic Brain Injury | Cerebral Edema
-
Rigel PharmaceuticalsCompletedAsthmaUnited States, Canada
-
Korea University Anam HospitalCompletedHealthyKorea, Republic of
-
Shanghai Pharmaceuticals Holding Co., LtdCompletedChronic Abnormal Immune Activation in HIV/AIDSChina
-
Philip Morris Products S.A.CompletedPharmacokineticsRussian Federation
-
Centre Hospitalier Universitaire de NīmesRecruiting